Investor Alert

April 12, 2021, 2:41 p.m. EDT

Novartis, Genentech get FDA OK of self-use Xolair

Watchlist Relevance

Want to see how this story relates to your watchlist?

Just add items to create a watchlist now:

or Cancel Already have a watchlist? Log In

By Colin Kellaher

Roche Holding AG's Genentech unit and Novartis AG on Monday said U.S. users of their blockbuster asthma treatment Xolair can now administer the drug themselves.

The companies said the U.S. Food and Drug Administration approved Xolair prefilled syringes for self-injection across all approved U.S. indications.

Xolair, which was first approved in the U.S. in 2003 to treat allergic asthma and is now also approved for chronic idiopathic urticaria and nasal polyps, previously required administration by a healthcare professional.

Novartis and Genentech, which work together to develop and co-promote Xolair in the U.S., said self-administration of the drug from home has become particularly important for patients who are considered at high risk amid the Covid-19 pandemic.

Write to Colin Kellaher at colin.kellaher@wsj.com

This Story has 0 Comments
Be the first to comment
More News In

Story Conversation

Commenting FAQs »

Partner Center

Link to MarketWatch's Slice.